Jeannie Baumann
jeannieb.bsky.social
Jeannie Baumann
@jeannieb.bsky.social
Newsletter editor for Bloomberg Government/ recovering health care journalist by day. Filmi and fitness fanatic all the time.
I wrote about this a while back. Can’t believe it’s actually been almost two years.

news.bloomberglaw.com/pharma-and-l...
Medicare Drug Price Guidance Leaves Murky Future for Rare Drugs
Rare disease patient advocates said Medicare’s final drug price implementation plan threatens to undo incentives to develop drugs for their patients, and they plan to increase pressure on Capitol Hill...
news.bloomberglaw.com
May 12, 2025 at 3:37 PM
At the same time, orphan drugs are some of the costliest ones on the market right now
May 12, 2025 at 3:35 PM
In the Medicare guidance document, CMS made clear they would lift the price, negotiation, exemption, even if the drug has not been approved for the additional indications. Obviously some groups were not happy about that and were looking to change it
May 12, 2025 at 3:34 PM
a key point here is that FDA grants the orphan drug designation **before** approval. So you don’t know that the drug will actually work on multiple diseases or populations just because there’s a design designation for that indication
May 12, 2025 at 3:34 PM
But back to the orphan drug provision in the E&C reconciliation text. Some background:

The Inflation Reduction Act exempts drugs with an FDA orphan drug designation from Medicare drug price negotiations.

But if there is more than one Orphan Drug designation, that exemption no longer applies.
May 12, 2025 at 3:31 PM
“That includes things like keeping the lights on, maintaining the facilities, and running institutional review boards to look at human subject [study] applications,” Collins said at a May 17, 2017 hearing.

news.bloomberglaw.com/pharma-and-l...
Cutting NIH Funds for ‘Indirect’ Research Costs Not Sustainable for Universities
Forcing universities to shoulder a greater share of the “indirect” costs of grant-funded studies may make their biomedical research efforts unsustainable, the agency’s director told House appropriator...
news.bloomberglaw.com
February 8, 2025 at 3:33 AM
Francis Collins told the house spending panel at the time that forcing universities to shoulder a greater share of the “indirect” costs of grant-funded studies may make their biomedical research efforts unsustainable.
February 8, 2025 at 3:32 AM
Reps. Tom Cole (R-Okla.) and Rosa DeLauro (R-Conn.), then the top GOP & Dem on Labor-H stopped the cuts. They now lead the full committee

But Rep. Andy Harris (R-Md.) was a big proponent of cutting F&A, saying that money could fund more research.
February 8, 2025 at 3:30 AM
Trump 1.0 proposed similar cuts in a budget blueprint they released almost eight years ago (March 16, 2017) as part of a larger effort to slash NIH's budget by $6 billion ($32B down to $25.9B).

news.bloomberglaw.com/pharma-and-l...
Will Trump's Budget Pull Back on Repaying Indirect Research Costs?
An ambiguous line in the preview of President Donald Trump’s first proposed budget indicates the NIH may cover fewer indirect research costs in the future.
news.bloomberglaw.com
February 8, 2025 at 3:27 AM
Wish I had written that with fewer typos🤦🏻‍♀️🤦🏻‍♀️🤣🤣 but yes exactly
January 31, 2025 at 2:35 PM